GCG

The C-8 Medical Monitoring Program is a vital initiative established as part of a court-approved settlement related to the release of ammonium perfluorooctanoate (C-8) from DuPont's Washington Works Plant into local drinking water. Launched in 2014, this program offers free screening tests to eligible class members affected by the probable health links identified by the C-8 Science Panel, which conducted extensive research into the health impacts of C-8 exposure. The panel recognized probable links between C-8 and several health conditions, including kidney cancer, pregnancy-induced hypertension, and thyroid disease, prompting the need for ongoing medical monitoring.

Participants can access comprehensive screening services, including questionnaires, physical exams, and lab tests—all at no cost. The program aims to provide early detection and management of potential health issues while encouraging Class Members to engage with knowledgeable healthcare professionals. In addition, participants may contribute to valuable health data, helping to inform future monitoring practices. The C-8 Medical Monitoring Program emphasizes both individual health and community well-being. For more information or to schedule an appointment, individuals can call 1-888-499-2553.